Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Tafasitamab
Related studies linked through entity extraction aliases.
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1